HRS-2261 / Jiangsu Hengrui Pharma - LARVOL DELTA

Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. (PubMed, Clin Pharmacokinet) - P1 | "HRS-2261 demonstrated good tolerability, with a low incidence of dysgeusia. The PK profile was favorable. This study supports further development of HRS-2261 as a potential P2X3 receptor antagonist for chronic cough."

Clinical • Journal • P1 data • PK/PD data • Chronic Cough • Cough • Pulmonary Disease • Respiratory Diseases

A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough (clinicaltrials.gov) - P2 | N=304 | Enrolling by invitation | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Chronic Cough • Cough • Pulmonary Disease • Respiratory Diseases

A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration (clinicaltrials.gov) - P1 | N=92 | Completed | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Active, not recruiting ➔ Completed

Trial completion • Chronic Cough • Cough • Pulmonary Disease • Respiratory Diseases

A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough (clinicaltrials.gov) - P2 | N=304 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P2 trial • Chronic Cough • Cough • Pulmonary Disease • Respiratory Diseases